Blinatumomab-induced T cell activation at single cell transcriptome resolution

BACKGROUND: Bi-specific T-cell engager (BiTE) antibody is a class of bispecific antibodies designed for cancer immunotherapy. Blinatumomab is the first approved BiTE to treat acute B cell lymphoblastic leukemia (B-ALL). It brings killer T and target B cells into close proximity, activating patient’s...

Descripción completa

Detalles Bibliográficos
Autores principales: Huo, Yi, Sheng, Zhen, Lu, Daniel R., Ellwanger, Daniel C., Li, Chi-Ming, Homann, Oliver, Wang, Songli, Yin, Hong, Ren, Ruibao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7923532/
https://www.ncbi.nlm.nih.gov/pubmed/33648458
http://dx.doi.org/10.1186/s12864-021-07435-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7923532/
https://www.ncbi.nlm.nih.gov/pubmed/33648458
http://dx.doi.org/10.1186/s12864-021-07435-2

Ejemplares similares